Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04698512
Other study ID # MATILDA
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 21, 2019
Est. completion date January 30, 2021

Study information

Verified date March 2021
Source Singapore General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

For patients with End Stage Renal Failure (ESRF), the surgical creation of an Autogenous Arteriovenous Fistula (AVF) or Autogenous Arteriovenous Graft (AVG) is the recognised standard for providing vascular access. A functioning dialysis vascular access is essential to facilitate hemodialysis (HD) treatment. Advantages include improved hemodialysis initiation time, improved dialysis quality, better maintenance of accesses and generally, better outcomes in patients. Unfortunately almost 50% of AVF and AVG fail after a median lifetime of 3 to 7 years and 12 to 18 months respectively. Vascular access dysfunction is a major cause of morbidity and hospitalisation for ESRF patients, costing the healthcare system USD 18 million globally. Venous stenosis and scarring are caused by trauma from surgical access creation when the circuit comes arterialized and from repeated percutaneous punctures from subsequent hemodialysis. This study is performed to evaluate Sirolimus-coated balloon efficacy and safety using MagicTouch™ Drug coated balloon catheter (Concept Medical Inc, Tampa, FL, US) on AVF patency with de novo and recurrent stenosis.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date January 30, 2021
Est. primary completion date January 16, 2020
Accepts healthy volunteers No
Gender All
Age group 21 Years to 90 Years
Eligibility Inclusion Criteria: - Informed consent was obtained - Patient aged = 21 and = 90 years - Native AVF was created more than 2 months prior to index procedure and had undergone 10 or more haemodialysis sessions utilizing two needles - Target lesion location had to be located between the anastomoses to the axillary-subclavian vein junction, as defined by insertion of the cephalic vein - On initial fistulogram, target lesions stenosis had to be =50 on angiographic assessment and in keeping with the clinical indicator for intervention - Stenosis had to <12cm in length (to allow for potential treatment with one SCB (length 15cm) only - Stenosis had to be initially treated successfully with a high-pressure plain balloon prior to SCB treatment as defined by:- (A) no clinically significant dissection (flow limiting) (B) no extravasation requiring treatment/stenting (C) residual stenosis =30% by angiographic measurement (D) Ability to completely efface the lesion waist using the pre-dilation balloon - No more than one additional ("nontarget") lesion in the access circuit that had to be also successfully treated (=30% residual stenosis) before drug elution. Separate lesion was defined by at least 3cm in distance from the target lesion. - Reference vessel diameter 5mm-8mm Exclusion Criteria: - Women who were preganant, lactating, or planning on becoming pregnant during the study - Subject had more than 2 lesions in the access circuit - Subject had a secondary non-target lesion that could not be successfully treated - Sepsis or active infection - Asymptomatic target lesions - A thrombosed access or an access with thrombosis treated = 30 days prior to index procedure - Surgical revision of the access site performed, planned or expected = 3months before or after the index procedure - Patients who were taking immunosuppressive therapy or are routinely taking =15 mg prednisone per day - Currently participating in another investigational drug, biologic, or device study involving Sirolimus or paclitaxel - Contraindication to Aspirin or Clopidogrel usage - Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, or language barrier such that the subject is unable to give informed consent - Uncooperative attitude or potential for non-compliance with the requirements of the protocol making study participation impractical - Where final angioplasty treatment requires a stent or drug eluting balloon >8mm in diameter - Metastatic cancer or terminal medical condition - Blood coagulation disorders - Limited life expectancy (<12 months) - Allergy or other know contraindication to iodinated media contrast, heparin, or Sirolimus

Study Design


Intervention

Device:
AVFistuloplasty with Sirolimus coated balloon
After an initial fistulogram, the lesion will first be predicated with standard high pressure balloon, followed by MagicTouch™ Sirolimus drug coated balloon

Locations

Country Name City State
Singapore Singapore General Hospital Singapore

Sponsors (1)

Lead Sponsor Collaborator
Singapore General Hospital

Country where clinical trial is conducted

Singapore, 

References & Publications (2)

Lee T, Roy-Chaudhury P. Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv Chronic Kidney Dis. 2009 Sep;16(5):329-38. doi: 10.1053/j.ackd.2009.06.009. Review. — View Citation

Pantelias K, Grapsa E. Vascular access today. World J Nephrol. 2012 Jun 6;1(3):69-78. doi: 10.5527/wjn.v1.i3.69. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Target Lesion Primary Patency No need for clinically driven reintervention of target lesion, no access thrombosis and no significant restenosis (lumen diameter <2.7mm) on duplex ultrasound 3-months post op
Primary Target Lesion Primary Patency No need for clinically driven reintervention of target lesion, no access thrombosis and no significant restenosis (lumen diameter <2.7mm) on duplex ultrasound 6-months post op
Primary Freedom from localised or systemic serious adverse events Include life-threatening events or those resulting in death, requiring hospitalisation, resulting in permanent disability, or requiring intervention to prevent permanent impairment 30 days post-op
Secondary Access circuit patency Lack of stenosis in any region of the AVF circuit requiring intervention 3 and 6 months post op
Secondary Procedural success Defined as technical success with at least one indicator of hemodynamic or clinical success. I.e. no conduit rupture during any of the procedures requiring bailout stenting. Day of operation
Secondary Primary assisted patency Lack of access circuit thrombosis requiring thrombolysis 3 and 6 months post op
Secondary Number of open bypass revision surgery required to maintain access circuit primary patency 3 and 6 months post op
Secondary Secondary access patency Lack of dialysis access abandonment 3 and 6 months post-op
Secondary Number of interventions required to maintain access circuit primary patency 3 and 6 months post-op
Secondary Event of mortality 6 months post-op
See also
  Status Clinical Trial Phase
Completed NCT04076488 - Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases N/A
Completed NCT03289650 - Extended Release Tacrolimus vs. Twice-Daily Tacrolimus Phase 3
Completed NCT04042324 - A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients Phase 1/Phase 2
Completed NCT01242904 - Use of a Bimodal Solution for Peritoneal Dialysis Phase 2
Active, not recruiting NCT03183245 - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis Phase 3
Completed NCT03257410 - Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients N/A
Completed NCT03627299 - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Phase 4
Recruiting NCT05917795 - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates N/A
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A
Withdrawn NCT02130817 - Belatacept in Kidney Transplantation of Moderately Sensitized Patients Phase 4
Completed NCT05540457 - Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis) N/A
Not yet recruiting NCT04900610 - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis N/A
Recruiting NCT02176434 - Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease N/A
Active, not recruiting NCT02581449 - Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis Phase 2
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Completed NCT02215655 - Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence N/A
Completed NCT02832466 - Quantifying the Deterioration of Physical Function in Renal Patients N/A
Completed NCT02832440 - Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis N/A
Completed NCT02830490 - Reliability of Functional Measures in Hemodialysis Patient. N/A
Recruiting NCT01912001 - Virtual Ward for Home Dialysis N/A